- Home
- ATAI vs OCS Comparison
ATAI vs OCS Comparison
Compare ATAI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | OCS |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | Netherlands | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | OCS |
|---|---|---|
| Price | $3.99 | $19.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $14.33 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 3.2M | 111.3K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,018,000.00 | $991,999.00 |
| Revenue This Year | $943.18 | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $14.00 |
| 52 Week High | $6.75 | $23.08 |
Technical Indicators
Market Signals| Indicator | ATAI | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 47.03 |
| Support Level | $3.88 | $20.18 |
| Resistance Level | $4.72 | $21.11 |
| Average True Range (ATR) | 0.24 | 0.69 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 13.10 | 27.83 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.